Trials / Completed
CompletedNCT01783548
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, Once Daily) in Pediatric Subjects (4 to 11 Years of Age) With PAR
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 547 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 4 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Beclomethasone dipropionate (BDP) nasal aerosol in subjects with Perennial Allergic Rhinitis (PAR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BDP Nasal Aerosol | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2013-02-05
- Last updated
- 2015-10-12
- Results posted
- 2015-10-12
Locations
63 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01783548. Inclusion in this directory is not an endorsement.